Phrenic nerve-hemidiaphragm as a highly sensitive replacement assay for determination of functional botulinum toxin antibodies

Toxicon

Volumn 57, Issue 7-8, 2011, Pages 1008-1016

  Rasetti Escargueil, C ^a   Liu, Y ^a   Rigsby, P ^a   Jones, R G A ^a   Sesardic, D ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Antibodies; Assays; Botulinum neurotoxin; Ex vivo; In vivo; Paralysis; Phrenic nerve hemidiaphragm

Indexed keywords

BOTULINUM ANTISERUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BIOASSAY; BOTULISM; CONTROLLED STUDY; EX VIVO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; MALE; MOUSE; NONHUMAN; PHRENIC NERVE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROTYPE;

ANIMALS; BOTULINUM ANTITOXIN; DIAPHRAGM; IMMUNOASSAY; IMMUNOLOGIC FACTORS; MALE; MICE; MICE, INBRED BALB C; PHENYTOIN; PHRENIC NERVE; SENSITIVITY AND SPECIFICITY; TOXICOLOGY;

ANIMALIA;

EID: 79956338948     PISSN: 00410101     EISSN: 18793150     Source Type: Journal    
DOI: 10.1016/j.toxicon.2011.04.003     Document Type: Article

References (51)

1. Boyer A.E., Moura H., Woolfitt A.R., Kalb S.R., McWilliams L.G., Pavlopoulos A., Schmidt J.G., Ashley D.L., Barr J.R. From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry. Anal. Chem. 2005, 77:3916-3924.
2. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb. Mortal. Wkly. Rep. 2010, 59:299. CDC.
3. Demarchi J., Mourgues S.C., Orio J., Prevot A.R. Existence of type D botulism in man. Bull. Acad. Natl. Med. 1958, 142:580-582.
4. Dolly J.O., Lande S., Wray D.W. The effects of in vitro application of purified botulinum neurotoxin at mouse motor nerve terminals. J.Physiol. 1987, 386:475-484.
5. Dolly J.O., Lawrence G.W., Meng J., Wang J., Ovsepian S.V. Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics. Curr. Opin. Pharmacol. 2009, 9:326-335.
6. Dong M., Richards D.A., Goodnough M.C., Tepp W.H., Johnson E.A., Chapman E.R. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell Biol. 2003, 162:1293-1303.
7. Dong M., Tepp W.H., Johnson E.A., Chapman E.R. Using fluorescent sensors to detect botulinum neurotoxin activity in vitro and in living cells. Proc. Natl. Acad. Sci. U. S. A 2004, 101:14701-14706.
8. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312:592-596.
9. Dressler D., Lange M., Bigalke H. Mouse diaphragm assay for detection of antibodies against botulinum toxin type B. Mov Disord. 2005, 20:1617-1619.
10. Eubanks L.M., Dickerson T.J., Janda K.D. Technological advancements for the detection of and protection against biological and chemical warfare agents. Chem. Soc. Rev. 2007, 36:458-470.
11. Botulinum toxin Type A for injection, 01/2008:0085. Eur. Pharmacopoeia 2011, 7. European Pharmacopoeia.
12. Ferracci G., Miquelis R., Kozaki S., Seagar M., Leveque C. Synaptic vesicle chips to assay botulinum neurotoxins. Biochem. J. 2005, 391:659-666.
13. Gill T.J. The use of randomly bred and genetically defined animals in biomedical research. Am. J. Pathol. 1980, 101:S21-S32.
14. Goschel H., Wohlfarth K., Frevert J., Dengler R., Bigalke H. Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp. Neurol. 1997, 147:96-102.
15. Hanson M.A., Stevens R.C. Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 A resolution. Nat. Struct. Biol. 2000, 7:687-692.
16. Huber A., France R.M., Riccalton-Banks L., McLaren J., Cox H., Quirk R.A., Shakesheff K.M., Thompson D., Panjwani N., Shipley S., Pickett A. The Intercostal NMJ assay: a new alternative to the conventional LD50 assay for the determination of the therapeutic potency of botulinum toxin preparations. Altern. Lab. Anim. 2008, 36:141-152.
17. Jankovic J. Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiatry 2004, 75:951-957.
18. Jones R.G.A., Alsop T.A., Hull R., Tierney R., Rigsby P., Holley J., Sesardic D. Botulinum Type A toxin neutralisation by specific IgG and its fragments: a comparison of mouse systemic toxicity and local flaccid paralysis assays. Toxicon 2006, 48:246-254.
19. Jones R.G.A., Corbel M.J., Sesardic D. A review of WHO International Standards for botulinum antitoxins. Biologicals 2006, 34:223-226.
20. Jones R.G.A., Ochiai M., Liu Y., Ekong T., Sesardic D. Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. J. Immunol. Methods 2008, 329:92-101.
21. Kalandakanond S., Coffield J.A. Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. J. Pharmacol. Exp. Ther. 2001, 296:980-986.
22. Keller J.E., Cai F., Neale E.A. Uptake of botulinum neurotoxin into cultured neurons. Biochemistry 2004, 43:526-532.
23. Lacy D.B., Tepp W., Cohen A.C., DasGupta B.R., Stevens R.C. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 1998, 5:898-902.
24. Lin L.I.K. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989, 45:255-268.
25. Meyer K. Medical progress, food poisoning. New Engl. J. Med. 1953, 249:843-852.
26. Nishiki T., Kamata Y., Nemoto Y., Omori A., Ito T., Takahashi M., Kozaki S. Identification of protein receptor for Clostridium botulinum Type B neurotoxin in rat brain synaptosomes. J. Biol. Chem. 1994, 269:10498-10503.
27. Pellett S., Tepp W.H., Clancy C.M., Borodic G.E., Johnson E.A. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett. 2007, 581:4803-4808.
28. Pellett S., Tepp W.H., Toth S.I., Johnson E.A. Comparison of the primary rat spinal cord cell (RSC) assay and the mouse bioassay for botulinum neurotoxin type A potency determination. J. Pharmacol. Toxicol. Methods 2010, 61:304-310.
29. Prevot A.R., Brygoo E.R. New investigations on botulinism and its five toxic types. Ann. Inst. Pasteur (Paris) 1953, 85:544-575.
30. Purkiss J.R., Friis L.M., Doward S., Quinn C.P. Clostridium botulinum neurotoxins act with a wide range of potencies on SH-SY5Y human neuroblastoma cells. Neurotoxicology 2001, 22:447-453.
31. Rasetti-Escargueil C., Jones R.G.A., Liu Y., Sesardic D. Measurement of botulinum types A, B and E neurotoxicity using the phrenic nerve-hemidiaphragm: improved precision with in-bred mice. Toxicon 2009, 53:503-511.
32. Rega P., Burkholder-Allen K., Bork C. An algorithm for the evaluation and management of red, yellow, and green zone patients during a botulism mass casualty incident. Am. J. Disaster Med. 2009, 4:192-198.
33. Rummel A., Eichner T., Weil T., Karnath T., Gutcaits A., Mahrhold S., Sandhoff K., Proia R.L., Acharya K.R., Bigalke H., Binz T. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc. Natl. Acad. Sci. U. S. A 2007, 104:359-364.
34. Rummel A., Hafner K., Mahrhold S., Darashchonak N., Holt M., Jahn R., Beermann S., Karnath T., Bigalke H., Binz T. Botulinum neurotoxins C, E and F bind gangliosides via a conserved binding site prior to stimulation-dependent uptake with botulinum neurotoxin F utilising the three isoforms of SV2 as second receptor. J. Neurochem. 2009, 110:1942-1954.
35. Rummel A., Karnath T., Henke T., Bigalke H., Binz T. Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J. Biol. Chem. 2004, 279:30865-30870.
36. Schiavo G., Benfenati F., Poulain B., Rossetto O., Polverino de L.P., DasGupta B.R., Montecucco C. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359:832-835.
37. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80:717-766.
38. Sesardic D., Gaines-Das R. Botulinum Toxin: Applying the 3Rs to Product Potency Testing 2009, National Centre for the Replacement, Refinement and Reduction of Animals in Research.
39. Sesardic D., Jones R.G.A., Leung T., Alsop T., Tierney R. Detection of antibodies against botulinum toxins. Mov Disord. 2004, 19(Suppl. 8):S85-S91.
40. Sesardic D., Mclellan K., Ekong T.A., Das R.G. Refinement and validation of an alternative bioassay for potency testing of therapeutic botulinum type A toxin. Pharmacol. Toxicol. 1996, 78:283-288.
41. Sheridan R.E., Deshpande S.S., Smith T. Comparison of in vivo and in vitro mouse bioassays for botulinum toxin antagonists. J. Appl.Toxicol. 1999, 19(Suppl. 1):S29-S33.
42. Simpson L.L. The interaction between divalent cations and botulinum toxin type A in the paralysis of the rat phrenic nerve-hemidiaphragm preparation. Neuropharmacology 1973, 12:165-176.
43. Simpson L.L. Studies on the binding of botulinum toxin type A to the rat phrenic nerve-hemidiaphragm preparation. Neuropharmacology 1974, 13:683-691.
44. Simpson L.L. Studies on the mechanism of action of botulinum toxin. Adv. Cytopharmacol 1979, 3:27-34.
45. Simpson L.L. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol. Rev. 1981, 33:155-188.
46. Simpson L.L., Coffield J.A., Bakry N. Chelation of zinc antagonizes the neuromuscular blocking properties of the seven serotypes of botulinum neurotoxin as well as tetanus toxin. J. Pharmacol. Exp. Ther. 1993, 267:720-727.
47. Simpson L.L., Morimoto H. Failure to inhibit in vitro or in vivo acetycholinesterase with botulinum toxin type A. J. Bacteriol. 1969, 97:571-575.
48. Simpson L.L., Tapp J.T. Actions of calcium and magnesium on the rate of onset of botulinum toxin paralysis of the rat diaphragm. Int. J. Neuropharmacol 1967, 6:485-492.
49. Singh B.R. Intimate details of the most poisonous poison. Nat. Struct. Biol. 2000, 7:617-619.
50. Straughan D. Progress in applying the Three Rs to the potency testing of Botulinum toxin Type A. Altern. Lab. Anim. 2006, 34:305-313.
51. Williamson L.C., Halpern J.L., Montecucco C., Brown J.E., Neale E.A. Clostridial neurotoxins and substrate proteolysis in intact neurons: botulinum neurotoxin C acts on synaptosomal-associated protein of 25 kDa. J. Biol. Chem. 1996, 271:7694-7699.